Hyperthermia and multiorgan failure after abuse of "bath salts" containing 3,4-methylenedioxypyrovalerone

Annals of Emergency Medicine

Volumn 60, Issue 1, 2012, Pages 103-105

  Borek, Heather A ^a   Holstege, Christopher P ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYPYROVALERONE; BATH SALT; BENZODIAZEPINE; CATHINONE; PYROVALERONE; UNCLASSIFIED DRUG;

ADULT; AGITATION; ARTICLE; ARTIFICIAL VENTILATION; BLOOD CHEMISTRY; CASE REPORT; DIALYSIS; DRUG SCREENING; ENDOTRACHEAL INTUBATION; HEART INJURY; HUMAN; HYPERTHERMIA; INDUCED HYPOTHERMIA; KIDNEY FAILURE; LABORATORY DIAGNOSIS; LIVER INJURY; MALE; MULTIPLE ORGAN FAILURE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RHABDOMYOLYSIS; SINUS TACHYCARDIA; TACHYCARDIA; URINALYSIS;

ADULT; BENZODIOXOLES; DESIGNER DRUGS; FEVER; HUMANS; MALE; MULTIPLE ORGAN FAILURE; PYRROLIDINES;

EID: 84860488942     PISSN: 01960644     EISSN: 10976760     Source Type: Journal    
DOI: 10.1016/j.annemergmed.2012.01.005     Document Type: Article

References (14)

1. Centers for Disease Control and Prevention. Emergency department visits after use of a drug sold as "bath salts " - Michigan, November 13, 2010-March 31, 2011. MMWR Morb Mortal Wkly Rep. 2011;60:624-627.
2. Kriikku P, Wilhelm L, Schwarz O, et al. New designer drug of abuse: 3,4-methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland. Forensic Sci Int. 2011;210:195-200.
3. Meltzer PC, Butler D, Deschamps JR, et al. 1-(4-Methylphenyl)-2- pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006;49: 1420-1432.
4. Brandt SD, Freeman S, Sumnall HR, et al. Analysis of NRG "legal highs" in the UK: identification and formation of novel cathinones. Drug Test Anal. 2010;3:569-575.
5. Uchiyama N, Kikura-Hanajiri R, Kawahara N, et al. Yakugaku Zasshi. 2008;128:1499-1505.
6. Coppola M, Mondola R. 3,4-Methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol Lett. 2012; 208:12-15.
7. Ross EA, Watson M, Goldberger B. "Bath salts" intoxication. N Engl J Med. 2011;365:967-968.
8. Rusyniak DE, Sprague JE. Toxin-induced hyperthermic syndromes. Med Clin North Am. 2005;89:1277-1296.
9. Rusyniak DE, Tandy SL, Hekmatyar SK, et al. The role of mitochondrial uncoupling in 3,4-methylenedioxymethamphetamine-mediated skeletal muscle hyperthermia and rhabdomyolysis. J Pharmacol Exp Ther. 2005;313:629-639.
10. Ojanpera IA, Heikman PK, Rasanen IJ. Urine analysis of 3,4- methylenedioxypyrovalerone in opioid-dependent patients by gas chromatography-mass spectrometry. Ther Drug Monit. 2011;33: 257-263.
11. Penders TM, Gestring R. Hallucinatory delirium following use of MDPV: "bath salts." Gen Hosp Psychiatry. 2011;33:525-526.
12. Antonowicz JL, Metzger AK, Ramanujam SL. Paranoid psychosis induced by consumption of methylenedioxypyrovalerone: two cases. Gen Hosp Psychiatry. 2012;33:640.
13. Striebel JM, Pierre JM. Acute psychotic sequelae of "bath salts."Schizophr Res. 2011;133:259-260.
14. Spiller HA, Ryan ML, Weston RG, et al. Clinical experience with and analytical confirmation of "bath salts" and "legal highs"(synthetic cathinones) in the United States. Clin Toxicol. 2011; 49:499-505.